| __timestamp | CRISPR Therapeutics AG | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 7751000 |
| Thursday, January 1, 2015 | 13403000 | 10251000 |
| Friday, January 1, 2016 | 31056000 | 9575000 |
| Sunday, January 1, 2017 | 35845000 | 10912000 |
| Monday, January 1, 2018 | 48294000 | 11049000 |
| Tuesday, January 1, 2019 | 63488000 | 11646000 |
| Wednesday, January 1, 2020 | 88208000 | 13265000 |
| Friday, January 1, 2021 | 102802000 | 25805000 |
| Saturday, January 1, 2022 | 102464000 | 35182000 |
| Sunday, January 1, 2023 | 76162000 | 94999000 |
| Monday, January 1, 2024 | 72977000 |
Data in motion
In the rapidly evolving biotech industry, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and Viridian Therapeutics, Inc. over the past decade. From 2014 to 2023, CRISPR Therapeutics AG has consistently outpaced Viridian Therapeutics, Inc. in SG&A spending, peaking in 2021 with expenses reaching approximately 102 million USD. This represents a staggering 1,900% increase from their 2014 figures. In contrast, Viridian Therapeutics, Inc. showed a more modest growth, with a notable surge in 2023, where their SG&A expenses nearly quadrupled from 2021 levels, reaching around 95 million USD. This trend highlights the strategic investments and scaling efforts by both companies, reflecting their commitment to innovation and market expansion. As the biotech landscape continues to shift, monitoring these financial metrics offers valuable insights into corporate strategies and market positioning.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG Trends and Insights
Breaking Down SG&A Expenses: GSK plc vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Xenon Pharmaceuticals Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Xencor, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared